Search

Your search keyword '"Brullet E"' showing total 207 results
Start Over Author "Brullet E"
207 results on '"Brullet E"'

1. USEFULNESS OF THE MODIFIED ROCKALL INDEX TO PREDICT ADVERSE EVENTS IN UPPER GASTROINTESTINAL BLEEDING DUE TO PEPTIC ULCER

Author

Pedregal, P., additional, Llovet, L., additional, Brunet, E., additional, Garcia-Iglesias, P., additional, Lira, A., additional, Machlab, S., additional, Grau, G., additional, Junquera, F., additional, Melcarne, L., additional, Puig-Diví, V., additional, Calvet, X., additional, Brullet, E., additional, and Martínez-Bauer, E., additional

Published
2022
Full Text
View/download PDF

2. Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial

Author

Loras C, Andujar X, Gornals J, Sanchiz V, Brullet E, Sicilia B, Martin-Arranz M, Naranjo A, Barrio J, Duenas C, Foruny J, Busquets D, Monfort D, Pineda J, Gonzalez-Huix F, Perez-Roldan F, Pons V, Gonzalez B, Reyes Moreno J, Sainz E, Guardiola J, Bosca-Watts M, Fernandez-Banares F, Mayor V, Esteve M, and Grupo Espanol de Trabajo de la Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)

Subjects
OUTCOMES, LONG-TERM, INTESTINAL STRICTURES, DILATATION, SAFETY, MANAGEMENT, EFFICACY, THERAPY, METAANALYSIS
Abstract

BACKGROUND: Endoscopic balloon dilation (EBD) is the established endoscopic treatment for short strictures in Crohn's disease. Fully covered self-expandable metal stents (FCSEMS) have been used for endoscopic treatment of patients for whom EBD was unsuccessful. We aimed to determine the efficacy and safety of the two endoscopic treatments in patients with Crohn's disease with stenosis and compare the mean cost of both treatments.; METHODS: This multicentre, open-label, randomised trial was done in 19 tertiary and secondary hospitals in Spain. Patients with Crohn's disease with obstructive symptoms and predominantly fibrotic strictures of less than 10 cm in length were eligible for inclusion. We excluded patients with stenosis treated with SEMS or EBD in the previous year and stenosis not accessible to a colonoscope. Patients were randomly assigned (1:1) to receive either EBD (EBD group) or FCSEMS (FCSEMS group) using a digital en-block randomisation system (block size of four). In the EBD group, dilation was done with a CRE Boston Scientific (Marlborough, MA, USA) pneumatic balloon with the diameter set at the discretion of the endoscopist; a maximum of two sessions of dilation were allowed with a minimum interval of 15-30 days between them. In the FCSEMS group, a 20 mm diameter Taewoong (Gimpo-si, South Korea) fully covered metal stent was placed; stent length was set at the discretion of the endoscopist. The primary outcome was to assess the efficacy of the endoscopic treatment, defined by the proportion of patients free of a new therapeutic intervention (EBD, FCSEMS, or surgery) due to symptomatic recurrence at 1 year of follow-up. Patients were analysed according to the intention-to-treat principle. Adverse events were recorded for all the patients; events were considered associated to be with the procedure when a causal association was possible, probable, or definite. This trial is registered with ClinicalTrials.gov, NCT02395354.; FINDINGS: From Aug 28, 2013, to Oct 9, 2017, we assessed the eligibility of 99 patients, of whom 19 (19%) patients were excluded. Thus, 80 (81%) patients were randomly assigned to treatment: 39 (49%) patients to the FCSEMS group and 41 (51%) patients to the EBD group. 33 (80%) of 41 patients in the EBD group and 20 (51%) of 39 patients in the FCSEMS group were free of a new therapeutic intervention at 1 year (odds ratio [OR] 3·9 [95% CI 1·4-10·6]; p=0·0061). Two (3%) of 80 patients had severe adverse events (one [2%] patient in the EBD group and one [3%] patient in the FCSEMS group); both patients had perforations.; INTERPRETATION: EBD is more effective than FCSEMS for Crohn's disease strictures, with a good safety profile for both treatments.; FUNDING: Spanish National Institute of Health, Foundation of Spanish Society of Digestive Endoscopy, Catalan Society of Gastroenterology, and Taweoong. Copyright © 2022 Elsevier Ltd. All rights reserved.

Published
2022

4. Comparable Quality of Bowel Preparation With Single‐Day Versus Three‐Day Low‐residue Diet: A Randomized Controlled Tria

Author

Machlab, S, additional, Martínez-Bauer, E, additional, López, P, additional, Puig-Diví, V, additional, Junquera, F, additional, Lira, A, additional, Hernández, L, additional, Brullet, E, additional, Selva, A, additional, García-Iglesias, P, additional, Vives, J, additional, Soria, A, additional, Pedregal, P, additional, Grau, G, additional, Calvet, X, additional, and Campo, R, additional

Published
2021
Full Text
View/download PDF

7. EFFECT OF A LOW RESIDUE DIET DURING ONE DAY VERSUS THREE DAYS ON BOWEL CLEANSING, DIET TOLERANCE AND COLONOSCOPY PERFORMANCE: A NON-INFERIORITY RANDOMISED CLINICAL TRIAL

Author

Machlab, S, additional, Martínez-Bauer, E, additional, López, P, additional, Lira, A, additional, Puig-Diví, V, additional, Junquera, F, additional, Selva, A, additional, García-Iglesias, P, additional, Hernández, L, additional, Brunet, E, additional, Vives, J, additional, Soria, A, additional, Brullet, E, additional, Calvet, X, additional, and Campo, R, additional

Published
2020
Full Text
View/download PDF

10. EFFECT OF WEEKEND HOSPITAL ADMISSION ON LOWER GASTROINTESTINAL BLEEDING OUTCOMES

Author

Machlab, S, additional, Garcia - Iglesias, P, additional, Martinez-Bauer, E, additional, Brunet, E, additional, Hernandez, L, additional, Marin, S, additional, Raurich, M, additional, Puig-Divi, V, additional, Melcarne, L, additional, Calvet, X, additional, Junquera, F, additional, Fernandez, RC, additional, Montero, MG, additional, Brullet, E, additional, and Lira, A, additional

Published
2020
Full Text
View/download PDF

12. MULTICENTER PROSPECTIVE RANDOMIZED STUDY TO COMPARE ENDOSCOPIC TREATMENT OF STRICTURES IN CROHN´S DISEASE (CD): SELF-EXPANDING METAL STENTS (SEMS) VS ENDOSCOPIC BALLOON DILATION (EBD). PROTDILAT STUDY

Author

Andújar, X, additional, Loras, C, additional, Gornals, JB, additional, Guardiola, J, additional, Sanchiz, V, additional, Bosca, M, additional, Brullet, E, additional, Sicilia, B, additional, Naranjo, A, additional, Dueñas, C, additional, Foruny, JR, additional, Busquets, D, additional, Monfort, D, additional, Martín-Arranz, MD, additional, Barrio, J, additional, Pineda, JR, additional, González-Huix, F, additional, Pérez-Roldán, F, additional, Pons, V, additional, González, B, additional, Sainz, E, additional, Reyes-Moreno, J, additional, Fernández-Bañares, F, additional, and Esteve, M, additional

Published
2020
Full Text
View/download PDF

13. Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis

Author

Rodríguez de Santiago E, Burgos-Santamaria D, Pérez-Carazo L, Brullet E, Ciriano L, Pons FR, Ángel de Jorge Turrión M, Prados S, Pérez-Corte D, Becerro-Gonzalez I, Martinez-Moneo E, Barturen A, Fernández-Urién I, López-Serrano A, Ferre-Aracil C, Lopez-Ibañez M, Carbonell C, Nogales O, Martínez-Bauer E, Lantarón ÁT, Pagano G, Vázquez-Sequeiros E, Albillos A, TC-325 collaboration project. Endoscopy group of the Spanish Association of Gast, García AG, Volpato N, Rodriguez-Escaja C, García-Alonso FJ, Sevilla-Ribota S, Marcos Prieto HM, Chavarría-Herbozo CM, Murcia O, Aranda-Hernández J, Borobia R, Lledó JG, Santander C, Coto D, Oyón D, Polo IO, González-Haba Ruíz M, Torres CF, De Benito Sanz M, Peñas B, Parejo S, Juzgado D, and Ibañez A

Abstract

Background and Aims: TC-325 (Hemospray, Cook Medical, Winston-Salem, NC) is an inorganic hemostatic powder recently approved by the U.S. Food and Drug Administration. This study aimed to examine the effectiveness, safety, and predictors of TC-325 failure in a large real-life cohort. Methods: This was a retrospective study conducted at 21 Spanish centers. All patients treated with TC-325 until September 2018 were included. The primary outcome was treatment failure, defined as failed intraprocedural hemostasis or recurrent bleeding within the first 30 postprocedural days. Secondary outcomes included safety and survival. Risk and predictors of failure were assessed via competing-risk models. Results: The cohort comprised 261 patients, of whom 219 (83.9%) presented with upper gastrointestinal bleeding (GIB). The most common causes were pepticulcer (28%), malignancy (18.4%), and therapeutic endoscopy-related GIB (17.6%). TC-325 was used as rescue therapy in 191 (73.2%) patients. The rate of intraprocedural hemostasis was 93.5% (95% confidence interval [CI], 90%-96%). Risks of TC-325 failure at postprocedural days 3, 7, and 30 were 21.1%, 24.6%, and 27.4%, respectively. On multivariate analysis, spurting bleeding (P = .004), use of vasoactive drugs (P = .02), and hypotension (P = .008) were independent predictors of failure. Overall 30-day survival was 81.9% (95% CI, 76%-86%) and intraprocedural hemostasis was associated with a better prognosis (adjusted hazard ratio, 0.29; P = .006). Two severe adverse events were noted. Conclusion: TC-325 was safe and effective for intraprocedural hemostasis in more than 90% of patients, regardless of the cause or site of bleeding and its use as rescue therapy. In this high-risk cohort treated with TC-325, the 30-day failure rate exceeded 25% and was highest with spurting bleeding or hemodynamic instability.

Published
2019

17. MUCOSAL ENDOSCOPIC RESECTION OF LARGE LESIONS OF THE UPPER DIGESTIVE TRACT

Author

Brunet Mas, E, additional, Martínez Bauer, E, additional, Garcia Iglesias, P, additional, Hernández, L, additional, Da Costa, J, additional, Llibre, G, additional, Soria, A, additional, Vives, J, additional, Pedregal, P, additional, Grau, G, additional, Lira, A, additional, Machlab, ST, additional, Melcarne, L, additional, Puig Diví, V, additional, Brullet, E, additional, Campo, R, additional, and Junquera, F, additional

Published
2019
Full Text
View/download PDF

18. HEMOSPRAY FOR GASTROINTESTINAL BLEEDING: EFFECTIVENESS, PREDICTORS OF FAILURE AND SURVIVAL IN A NATIONWIDE STUDY

Author

Rodríguez de Santiago, E, additional, Burgos Santamaría, D, additional, Pérez Carazo, L, additional, Teran Lantaron, A, additional, Brullet, E, additional, Prados Leira, S, additional, Riu Pons, F, additional, Fernández-Urién Sainz, I, additional, Becerro González, I, additional, Angel de Jorge Turrión, M, additional, Ferre Aracil, C, additional, Rodríguez Escaja, C, additional, Perez Corte, D, additional, Volpato Machado, N, additional, Martínez Moneo, E, additional, García Alonso, FJ, additional, Chavarría Herbozo, CM, additional, Sevilla Ribota, S, additional, Borobia Sanchez, R, additional, Martínez Bauer, E, additional, Ciriano Hernández, L, additional, Barturen Barroso, A, additional, Santander Vaquero, C, additional, Guerrero García, A, additional, Prieto, HMM, additional, López Serrano, A, additional, López Ibañez, M, additional, Murcia Palomares, O, additional, Pagano, G, additional, Oyón Lara, D, additional, Froilan Torres, C, additional, Coto Ugarte, D, additional, González-Haba Ruíz, M, additional, de Benito Sanz, M, additional, Carbonell Blanco, C, additional, Nogales Rincón, O, additional, Ortiz Polo, I, additional, Juzgado de Lucas, D, additional, Parejo Carbonell, S, additional, Peñas García, B, additional, Aranda Hernández, J, additional, García Lledó, J, additional, Ibañez Pinto, A, additional, Vazquez Sequeiros, E, additional, and Albillos, A, additional

Published
2019
Full Text
View/download PDF

19. OAKLAND SCORE IS NOT BETTER THAN HAEMOGLOBIN FOR PREDICTING OUTCOMES IN LOWER GASTROINTESTINAL BLEEDING

Author

Lira, A, additional, Machlab, S, additional, García-Iglesias, P, additional, Martínez-Bauer, E, additional, Mármol, C, additional, Gallach, M, additional, Hernández, L, additional, Brunet, E, additional, Melcarne, L, additional, Da Costa, J, additional, Llibre, G, additional, Puig-Diví, V, additional, Junquera, F, additional, Campo, R, additional, Calvet, X, additional, and Brullet, E, additional

Published
2019
Full Text
View/download PDF

20. GLASGOW-BLACHFORD SCORE ACCURATELY PREDICTS THE NEED OF CLINICAL INTERVENTION IN ACUTE LOWER GASTROINTESTINAL BLEEDING. A DIAGNOSTIC ACCURACY EVALUATION STUDY

Author

Lira, A, additional, Machlab, S, additional, Garcia-Iglesias, P, additional, Martinez-Bauer, E, additional, Mármol, C, additional, Llibre, G, additional, Da Costa, J, additional, Gallach, M, additional, Melcarne, L, additional, Puig-Diví, V, additional, Junquera, F, additional, Campo, R, additional, Calvet, X, additional, and Brullet, E, additional

Published
2019
Full Text
View/download PDF

22. The incidence of ulcer bleeding post endoscopic band ligation of esophageal varices

Author

Machlab, S., primary, Da Costa, J., additional, Horta, D., additional, Ruiz, P., additional, Profitós, J., additional, Gómez, M.V., additional, Miquel, M., additional, Casas, M., additional, Dalmau, B., additional, Campo, R., additional, Brullet, E., additional, Junquera, F., additional, Puig-Diví, V., additional, Martínez-Bauer, E., additional, García-Iglesias, P., additional, Villoria, A., additional, Gallach, M., additional, Melcarne, L., additional, Calvet, X., additional, and Sánchez-Delgado, J., additional

Published
2018
Full Text
View/download PDF

23. INCIDENCE AND OUTCOMES OF ENDOSCOPIC ESOPHAGEAL VARICEAL LIGATION-INDUCED ULCER BLEEDING

Author

Machlab, S, additional, da Costa, J, additional, Horta, D, additional, Ruiz, P, additional, Profitós, J, additional, Vergara, M, additional, Miquel, M, additional, Casas, M, additional, Dalmau, B, additional, Brullet, E, additional, Junquera, F, additional, Puig-Diví, V, additional, Martínez-Bauer, E, additional, Campo, R, additional, García-Iglesias, P, additional, and Sánchez-Delgado, J, additional

Published
2018
Full Text
View/download PDF

26. Estudio comparativo prospectivo multicéntrico aleatorizado del tratamiento endoscópico de las estenosis en la Enfermedad de Crohn: prótesis metálica autoexpandible vs. dilatación con balón (estudio PROTDILAT)

Author

Andújar Murcia, X, additional, Loras, C, additional, Gornals, JB, additional, Sanchiz, V, additional, Brullet, E, additional, Sicilia, B, additional, Naranjo, A, additional, Dueñas, C, additional, González-Huix, F, additional, and Esteve Comas, M, additional

Published
2017
Full Text
View/download PDF

29. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract

Author

Smith, L.A., Stanley, A.J., Bergman, J.J., Kiesslich, R., Hoffman, A., Tjwa, E.T., Kuipers, E.J., Holstein, C.S. von, Oberg, S., Brullet, E., Schmidt, P.N., Iqbal, T., Mangiavillano, B., Masci, E., Prat, F., Morris, A.J., Smith, L.A., Stanley, A.J., Bergman, J.J., Kiesslich, R., Hoffman, A., Tjwa, E.T., Kuipers, E.J., Holstein, C.S. von, Oberg, S., Brullet, E., Schmidt, P.N., Iqbal, T., Mangiavillano, B., Masci, E., Prat, F., and Morris, A.J.

Abstract

Item does not contain fulltext, BACKGROUND: Hemospray TM (TC-325) is a novel hemostatic agent licensed for use in nonvariceal upper gastrointestinal bleeding (NVUGIB) in Europe. GOALS: We present the operating characteristics and performance of TC-325 in the largest registry to date of patients presenting with NVUGIB in everyday clinical practice. METHODS: Prospective anonymized data of device performance and clinical outcomes were collected from 10 European centers using the multicentre SEAL survey (Survey to Evaluate the Application of Hemospray in the Luminal tract). TC-325 was used as a monotherapy or as second-line therapy in combination with other hemostatic modalities at the endoscopists' discretion. RESULTS: Sixty-three patients (44 men, 19 women), median age 69 (range, 21 to 98) years with NVUGIB requiring endoscopic hemostasis were treated with TC-325. There were 30 patients with bleeding ulcers and 33 with other NVUGIB pathology. Fifty-five (87%) were treated with TC-325 as monotherapy; 47 [85%; 95% confidence interval (CI), 76%-94%] of them achieved primary hemostasis, and rebleeding rate at 7 days was 15% (95% CI, 5%-25%). Primary hemostasis rate for TC-325 in patients with ulcer bleeds was 76% (95% CI, 59%-93%). Eight patients, who otherwise may have required either surgery or interventional radiology, were treated with TC-325 as second-line therapy after failure of other endoscopic treatments, all of whom achieved hemostasis following the adjunct of TC-325. CONCLUSIONS: This multicentre registry identifies potentially useful characteristics of Hemospray (TC-325) when used either as monotherapy or as a rescue therapy in a wide variety of ulcer and nonulcer NVUGIB.

Published
2014

30. Hemospray treatment is effective for lower gastrointestinal bleeding

Author

Holster, I.L., Brullet, E., Kuipers, E.J., Campo, R., Fernandez-Atutxa, A., Tjwa, E.T., Holster, I.L., Brullet, E., Kuipers, E.J., Campo, R., Fernandez-Atutxa, A., and Tjwa, E.T.

Abstract

Item does not contain fulltext, Acute lower gastrointestinal bleeding (LGIB) is diverse in origin and can be substantial, requiring urgent hemostasis. Hemospray is a promising novel hemostatic agent for upper gastrointestinal bleeding (UGIB). It has been claimed in a small series that the use of Hemospray is also feasible in LGIB. We aimed to expand our knowledge of the application of Hemospray for the treatment of LGIB in a wider range of conditions to further define the optimal patient population for this new therapeutic modality. We analyzed the outcomes of nine unselected consecutive patients with active LGIB treated with Hemospray in two major hospitals in Europe. Initial hemostasis was achieved after Hemospray application in all patients. Rebleeding occurred in two patients (22%) who were on acetyl salicylic acid and presented with spurting bleeds. These preliminary data show that Hemospray can be effective in the management of LGIB, but suggest cautious use for patients on antithrombotic therapy and spurting bleeds.

Published
2014

35. Vanishing duodenal varix: unreported presentation causing massive bleeding

Author

Brullet E, Campo R, Corcuera A, and Joseph D

Subjects
Male, medicine.medical_specialty, Varix, business.industry, Duodenum, Gastroenterology, Oleic Acids, Middle Aged, Sclerosing Solutions, Endoscopy, Gastrointestinal, Surgery, Varicose Veins, medicine.anatomical_structure, Massive bleeding, medicine, Humans, Treatment Failure, Presentation (obstetrics), business, Varices, Venous disease
Published
1996

36. JUICIO DEL ENDOSCOPISTA FRENTE A INDICES PRONÓSTICOS EN LA PREDICCIÓN DE RECIDIVA Y MORTALIDAD POR ULCUS SANGRANTE TRAS TRATAMIENTO ENDOSCÓPICO. RESULTADOS DE UN ESTUDIO PROSPECTIVO Y MULTICÉNTRICO

Author

García-Iglesias, P, primary, Brullet, E, additional, Calvet, X, additional, Papo, M, additional, Planella, M, additional, Junquera, F, additional, Martinez-Bauer, E, additional, Montoliu, S, additional, Pardo, A, additional, Ballester, R, additional, Casas, M, additional, Villoria, A, additional, Puig-Diví, V, additional, Miquel, M, additional, Vergara, M, additional, and Campo, R, additional

Published
2012
Full Text
View/download PDF

37. Editorial

Author

Vazquez-Sequeiros, E, primary, Brullet, E, additional, and Bordas, JM, additional

Published
2012
Full Text
View/download PDF

39. Clinical practice Guidelines: quality of colonoscopy in colorectal cancer screening

Author

Jover, R., primary, Herráiz, M., additional, Alarcón, O., additional, Brullet, E., additional, Bujanda, L., additional, Bustamante, M., additional, Campo, R., additional, Carreño, R., additional, Castells, A., additional, Cubiella, J., additional, García-Iglesias, P., additional, Hervás, A., additional, Menchén, P., additional, Ono, A., additional, Panadés, A., additional, Parra-Blanco, A., additional, Pellisé, M., additional, Ponce, M., additional, Quintero, E., additional, Reñé, J., additional, Sánchez del Río, A., additional, Seoane, A., additional, Serradesanferm, A., additional, Soriano Izquierdo, A., additional, and Vázquez Sequeiros, E., additional

Published
2012
Full Text
View/download PDF

41. Editorial de la SEED

Author

Brullet, E, primary, Vazquez Sequeiros, E, additional, Bordas, JM, additional, Martínez Alcalá, F, additional, and Menchén, P, additional

Published
2010
Full Text
View/download PDF

43. Borage consumption as a possible gastric cancer protective factor

Author

Ca, González, Jm, Sanz, Marcos G, Pita S, Brullet E, Saigi E, Badia A, Antonio Agudo, and Riboli E

Subjects
Magnoliopsida, Dietary Fats, Unsaturated, Linolenic Acids, Spain, Stomach Neoplasms, Fatty Acids, Anticarcinogenic Agents, Humans, Plant Oils, Feeding Behavior, Plants, Edible, gamma-Linolenic Acid
Published
1993

45. JUICIO CLINICO FRENTE MODELOS MATEMÁTICOS EN LA PREDICCIÓN DE RECIDIVA Y MORTALIDAD POR ULCERA PÉPTICA SANGRANTE. RESULTADOS PRELIMINARES DE UN ESUDIO PROSPECTIVO MULTICÉNTRICO

Author

Brullet, E., primary, Calvet, X., additional, Campo, R., additional, Papo, M., additional, Planella, M., additional, Junquera, F., additional, Garcia-Iglesias, P., additional, Montoliu, S., additional, Pardo, A., additional, Ballester, Rl., additional, Miquel, M., additional, Puig Diví, V., additional, Martinez-Bauer, E., additional, Villoria, A., additional, Gallach, M., additional, Casas, M., additional, and Vergara, M., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results